<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Few studies have been devoted to the natural history of cervical <z:e sem="disease" ids="C0002949" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">artery dissection</z:e> (CAD) </plain></SENT>
<SENT sid="1" pm="."><plain>This review shows that apart from neurological damage due to initial <z:hpo ids='HP_0001297'>stroke</z:hpo>, the prognosis of DAC is good </plain></SENT>
<SENT sid="2" pm="."><plain>Indeed, the risk of recurrent DAC or recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> is very low, under 1% per year in patients without typical <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> (<z:e sem="disease" ids="C0013720" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ehlers Danlos syndrome</z:e> or <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>) or familial history of <z:hpo ids='HP_0005294'>arterial dissection</z:hpo> have an increased risk of recurrent CAD </plain></SENT>
<SENT sid="4" pm="."><plain>However, the number of cases due to these diseases remains very low </plain></SENT>
<SENT sid="5" pm="."><plain>The other risk factors for recurrent CAD or <z:hpo ids='HP_0001297'>stroke</z:hpo> remain unknown </plain></SENT>
<SENT sid="6" pm="."><plain>The benefit of antithrombotic treatments at the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of CAD or for secondary prevention has been never assessed in a randomized clinical trial </plain></SENT>
</text></document>